ProShare Advisors’s Mineralys Therapeutics MLYS Stock Holding History

ProShare Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Sell	10,220 -239	-2%	-$6.56K	﹤0.01%	1473
2026 Q1	$283K	Sell	10,459 -1,581	-13%	-$46.4K	﹤0.01%	1371
2025 Q4	$437K	Buy	12,040 +2,985	+33%	+$120K	﹤0.01%	1208
2025 Q3	$343K	Sell	9,055 -1,402	-13%	-$30.3K	﹤0.01%	1331
2025 Q2	$141K	Buy	+10,457	New	+$152K	﹤0.01%	1802
2025 Q1	–	Sell	-10,405	Closed	-$128K	–	2189
2024 Q4	$128K	Buy	+10,405	New	+$136K	﹤0.01%	2014

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ProShare Advisors's MLYS Position: Q2 2026 in Review

ProShare Advisors reduced its Mineralys Therapeutics (MLYS) stake by 2.3% in Q2 2026, selling an estimated $6.56K and leaving 10,220 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

ProShare Advisors first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $437K in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

ProShare Advisors held 10,220 shares of Mineralys Therapeutics worth $276K as of Q2 2026.
ProShare Advisors sold 239 Mineralys Therapeutics shares in Q2 2026, an estimated $6.56K.
Mineralys Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1473 holding.
ProShare Advisors first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
ProShare Advisors's Mineralys Therapeutics position peaked at $437K in Q4 2025.
225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.